Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60611


Purpose:

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Treating the peripheral stem cells in the laboratory may improve the effectiveness of the transplant. PURPOSE: Phase I trial to study the effectiveness of peripheral stem cell transplantation in patients who have relapsed or refractory non-Hodgkin's lymphoma and who will be treated with high-dose chemotherapy.


Study summary:

OBJECTIVES: - Determine the toxicity of ex vivo expanded peripheral blood mononuclear cells (EVE PBMNC) as a supplement to high-dose chemotherapy and conventional autograft in patients with relapsed or refractory non-Hodgkin's lymphoma. - Compare the effect of EVE PBMNC on white blood cell, red blood cell, and platelet recovery in patients on this study vs historical controls, matched by protocol, disease status, and prior therapy. - Determine the optimal duration of culture and time of harvest for the production of neutrophils in vivo. - Determine the relationships between length of culture, immunophenotype, and clinical outcome. - Determine the required numbers of white blood cell precursors for clinical efficacy. - Assess the need for multiple transfusions of EVE PBMNC during the post-transplantation period. OUTLINE: Autologous peripheral blood mononuclear cells (PBMNC) are harvested. Unselected PBMNC are cultured and expanded ex vivo in flt3 ligand, interleukin-3, filgrastim (G-CSF), sargramostim (GM-CSF), and epoetin alfa for 13 days. Expanded PBMNC are reinfused on day 0. Patients are followed monthly for 1 year. PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically proven relapsed or refractory non-Hodgkin's lymphoma - Scheduled to undergo high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan) with autologous peripheral blood mononuclear cell transplantation - No metastatic disease involving the bone marrow PATIENT CHARACTERISTICS: Age: - 17 to 65 Performance status: - ECOG 0 or 1 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count greater than 100,000/mm^3 Hepatic: - No active hepatitis B or C - Bilirubin less than 2.5 times normal* - SGOT or SGPT less than 2.5 times normal* - Alkaline phosphatase less than 2.5 times normal NOTE: * Unless Gilbert's syndrome present Renal: - Creatinine clearance greater than 50 mL/min Cardiovascular: - Cardiac ejection fraction normal Pulmonary: - DLCO at least 50% predicted - FEV_1 and FVC at least 75% predicted Other: - HIV negative - Not pregnant - Negative pregnancy test - No non-neoplastic disease that would preclude intensive chemotherapy PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics Chemotherapy: - See Disease Characteristics Endocrine therapy: - Not specified Radiotherapy: - No prior external beam radiotherapy to more than 25% of the active bone marrow Surgery: - Not specified


NCT ID:

NCT00005787


Primary Contact:

Study Chair
Jane N. Winter, MD
Robert H. Lurie Cancer Center


Backup Contact:

N/A


Location Contact:

Chicago, Illinois 60611
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 23, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.